Peter O'Donnell, MD
Chair, Associate Professor of Medicine
Peter O’Donnell, MD is an Associate Professor of Medicine (Section of Hematology/Oncology), Chair of the Committee on Clinical Pharmacology and Pharmacogenomics. He is the Associate Director of Clinical Implementation and Deputy Director for the Center for Personalized Therapeutics. Dr. O’Donnell completed his Clinical Pharmacology and Pharmacogenomics training in 2010 and was board certified in Clinical Pharmacology in 2011. His research focuses on facilitating and understanding the delivery and adoption of pharmacogenomic information at the point-of-care to inform prescribing.
M. Eileen Dolan, PhD
Professor of Medicine
M. Eileen Dolan, PhD, Professor of Medicine, Section of Hematology/Oncology; Deputy Director, University of Chicago Comprehensive Cancer Center and Associate Director for Education, Center for Personalized Therapeutics.
Dr. Dolan is a pharmacologist working in the area of pharmacogenomics of anticancer agents. She is a leader in developing cell-based methods to identify genetic variants contributing to chemotherapeutic induced cytotoxicity through their effect on gene expression. Her laboratory is focused on identification of genetic variation contributing to chemotherapeutic response and toxicity using preclinical models and translating those findings into clinical trials.
Mark Ratain, MD
Leon O. Jacobson Professor of Medicine
Mark Ratain, MD, Leon O. Jacobson Professor of Medicine; Director, Center for Personalized Therapeutics; Associate Director for Clinical Sciences, the University of Chicago Comprehensive Cancer Center; Chief Hospital Pharmacologist for the University of Chicago Medical Center
Dr. Ratain is a hematology/oncologist and clinical pharmacologist whose research activities include both pharmacogenetics and antineoplastic drug development. Interests include genetic and non-genetic factors affecting the therapeutic index of irinotecan, a drug active in colorectal cancer and other solid tumors, factors affecting the therapeutic index of epidermal growth factor receptor inhibitors, genetic variation in glucuronosyltransferases, and methodological issues relevant to anticancer drug development.
Lexi nash smith
Program Administrator, Committee on Clinical Pharmacology and Pharmacogenomics